[Protein kinase C as a potential target for drug development in cancer research]

Related Experiment Video

Updated: Oct 13, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

P Acs1, G Paragh

  • 1Molecular Mechanisms of Tumor Promotion Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

Orvosi Hetilap
|September 9, 2000
PubMed

Insights

Protein Kinase C (PKC) is a key target for drug development due to its role in cellular signaling. Understanding PKC regulation offers opportunities for novel therapeutic strategies beyond cancer treatment.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Context:

  • Protein Kinase C (PKC) plays a central role in cellular signal transduction pathways.
  • Its regulation involves ligands, phosphorylation, and macromolecular interactions affecting localization.
  • Understanding these regulatory mechanisms is crucial for predicting cellular responses.

Purpose:

  • To explore the therapeutic potential of targeting Protein Kinase C (PKC).
  • To highlight the opportunities for developing specific interventions based on PKC isoform diversity and regulation.
  • To broaden the scope of PKC-targeted therapies beyond oncology.

Summary:

  • PKC's central role in signaling makes it a promising drug target.
  • Diverse PKC isoforms and context-specific regulation offer avenues for therapeutic specificity.
  • Novel strategies targeting PKC folding and localization complement existing inhibitor designs.

Impact:

  • Advances in understanding PKC regulation can predict cellular consequences of genetic or environmental changes.
  • The multiplicity of PKC isoforms allows for the development of highly specific therapeutics.
  • Targeting PKC offers broad opportunities in signal transduction-related diseases, extending beyond cancer.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...